M&A / Deals Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Pharmaceutical TechnologyBiogen's acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company's portfolio of medicines.M&A / DealsRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Biogen’s acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company’s portfolio of medicines. M&A / DealsRare DiseaseRead full story Post navigation Previous: Telomir seeks FDA approval for Telomir-1 to treat breast cancerNext: Agios mulls early FDA filing for sickle cell therapy Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
